October 18, 2021
Esteve Pharmaceuticals has received U.S. FDA approval for Seglentis® (celecoxib/ tramadol hydrochloride) to manage acute pain in adults that is severe enough to require an opioid analgesic and for which alternative treatments are inadequate.
- Seglentis combines two FDA-approved drugs into a single tablet: celecoxib, a non-steroidal anti- inflammatory drug (NSAID), and tramadol, an opioid.
- Recommended dosing is two tablets every 12 hours as needed for pain relief. According to the drug label, prescribing naloxone at the same time as Seglentis is recommended if the patient or members of the patient’s household have certain risk factors for opioid overdose.
- The product is expected to launch in 2022.